Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis

Open access
Cui, Jing, Stahl, Eli A., Saevarsdottir, Saedis, Miceli, Corinne, Diogo, Dorothee, Trynka, Gosia, Raj, Towfique, Mirkov, Maša Umiċeviċ, Canhao, Helena, Ikari, Katsunori, Terao, Chikashi, Okada, Yukinori, Wedrén, Sara, Askling, Johan, Yamanaka, Hisashi, Momohara, Shigeki, Taniguchi, Atsuo, Ohmura, Koichiro, Matsuda, Fumihiko, Mimori, Tsuneyo, Gupta, Namrata, Kuchroo, Manik, Morgan, Ann W., Isaacs, John D., Wilson, Anthony G., Hyrich, Kimme L., Herenius, Marieke, Doorenspleet, Marieke E., Tak, Paul-Peter, Crusius, J. Bart A., van der Horst-Bruinsma, Irene E., Wolbink, Gert Jan, van Riel, Piet L. C. M., van de Laar, Mart, Guchelaar, Henk-Jan, Shadick, Nancy A., Allaart, Cornelia F., Huizinga, Tom W. J., Toes, Rene E. M., Kimberly, Robert P., Bridges, S. Louis, Criswell, Lindsey A., Moreland, Larry W., Fonseca, João Eurico, de Vries, Niek, Stranger, Barbara E., De Jager, Philip L., Raychaudhuri, Soumya, Weinblatt, Michael E., Gregersen, Peter K., Mariette, Xavier, Barton, Anne, Padyukov, Leonid, Coenen, Marieke J. H., Karlson, Elizabeth W., Plenge, Robert M.·2013·PLoS Genetics

Abstract

Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumatoid arthritis (RA). It is unknown why some RA patients fail to respond adequately to anti-TNF therapy, which limits the development of clinical biomarkers to predict response or new drugs to target refractory cases. To understand the biological basis of response to anti-TNF therapy, we conducted a genome-wide association study (GWAS) meta-analysis of more than 2 million common variants in 2,706 RA patients from 13 different collections. Patients were treated with one of three anti-TNF medications: etanercept (n = 733), infliximab (n = 894), or adalimumab (n = 1,071). We identified a SNP (rs6427528) at the 1q23 locus that was associated with change in disease activity score (ΔDAS) in the etanercept subset of patients (P = 8 × 10(-8)), but not in the infliximab or adalimumab subsets (P>0.05). The SNP is predicted to disrupt transcription factor binding site motifs in the 3' UTR of an immune-related gene, CD84, and the allele associated with better response to etanercept was associated with higher CD84 gene expression in peripheral blood mononuclear cells (P = 1 × 10(-11) in 228 non-RA patients and P = 0.004 in 132 RA patients). Consistent with the genetic findings, higher CD84 gene expression correlated with lower cross-sectional DAS (P = 0.02, n = 210) and showed a non-significant trend for better ΔDAS in a subset of RA patients with gene expression data (n = 31, etanercept-treated). A small, multi-ethnic replication showed a non-significant trend towards an association among etanercept-treated RA patients of Portuguese ancestry (n = 139, P = 0.4), but no association among patients of Japanese ancestry (n = 151, P = 0.8). Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with disease activity. These findings support a model in which CD84 genotypes and/or expression may serve as a useful biomarker for response to etanercept treatment in RA patients of European ancestry.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1003394

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 164

Metadata

Authors
Cui, J., Stahl, E. A., Saevarsdottir, S., Miceli, C., Diogo, D., Trynka, G., Raj, T., Mirkov, M. U., Canhao, H., Ikari, K., Terao, C., Okada, Y., Wedrén, S., Askling, J., Yamanaka, H., Momohara, S., Taniguchi, A., Ohmura, K., Matsuda, F., Mimori, T., Gupta, N., Kuchroo, M., Morgan, A. W., Isaacs, J. D., Wilson, A. G., Hyrich, K. L., Herenius, M., Doorenspleet, M. E., Tak, P.-P., Crusius, J. B. A., van der Horst-Bruinsma, I. E., Wolbink, G. J., van Riel, P. L. C. M., van de Laar, M., Guchelaar, H.-J., Shadick, N. A., Allaart, C. F., Huizinga, T. W. J., Toes, R. E. M., Kimberly, R. P., Bridges, S. L., Criswell, L. A., Moreland, L. W., Fonseca, J. E., de Vries, N., Stranger, B. E., De Jager, P. L., Raychaudhuri, S., Weinblatt, M. E., Gregersen, P. K., Mariette, X., Barton, A., Padyukov, L., Coenen, M. J. H., Karlson, E. W., & Plenge, R. M.
Venue
PLoS Genetics
Published
2013-03-28
Volume
9
Issue
3
Pages
e1003394
ISSN
  • 1553-7390 (ISSN-L)
  • 1553-7404
OpenAlex
W2127106391
Cited by
164
References
9
FWCI
20.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. https://app.cochat.ai/papers/10.1371/journal.pgen.1003394
The paper
Cui, J., Stahl, E. A., Saevarsdottir, S., Miceli, C., Diogo, D., Trynka, G., Raj, T., Mirkov, M. U., Canhao, H., Ikari, K., Terao, C., Okada, Y., Wedrén, S., Askling, J., Yamanaka, H., Momohara, S., Taniguchi, A., Ohmura, K., Matsuda, F., . . . Plenge, R. M. (2013). Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics. https://doi.org/10.1371/journal.pgen.1003394

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.